These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26813471)

  • 1. Clinical study of double dose of valsartan combined with tacrolimus in treatment of diabetic nephropathy.
    Jin H; Zhang HN; Hou XL; Zhang B; Wu J; Zhang HB
    Eur Rev Med Pharmacol Sci; 2016; 20(1):174-9. PubMed ID: 26813471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
    Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
    Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis.
    Sun F; Jiang D; Cai J
    BMC Endocr Disord; 2021 Aug; 21(1):178. PubMed ID: 34465338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
    Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
    Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
    J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS).
    Peng DF; Tang SY; Hu YJ; Chen J; Peng X; Huang Q
    Eur Rev Med Pharmacol Sci; 2015 Apr; 19(7):1264-71. PubMed ID: 25912588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curative Effects of Valsartan Alone or Combined with Alpha-lipoic Acid on Inflammatory Cytokines and Renal Function in Early-stage Diabetic Kidney Disease.
    Jiang Z; Tan Z; Meng F; Li X
    J Coll Physicians Surg Pak; 2019 Oct; 29(10):1009-1011. PubMed ID: 31564281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of tacrolimus on podocytes in early diabetic nephropathy in rats.
    Peng T; Chang X; Wang J; Zhen J; Yang X; Hu Z
    Mol Med Rep; 2017 May; 15(5):3172-3178. PubMed ID: 28339051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study].
    Guo ZA; Yu CJ; Liu G; Meng FC; Li Y; Peng SL
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Sep; 34(9):1047-52. PubMed ID: 25335326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
    Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.
    Jo YI; Na HY; Moon JY; Han SW; Yang DH; Lee SH; Park HC; Choi HY; Lim SD; Kie JH; Lee YK; Shin SK
    Korean J Intern Med; 2016 Mar; 31(2):335-43. PubMed ID: 26874511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin II type 1 receptor antibody.
    Zhao LS; Bai WW; Xiang GD; Yue L; Sun HL
    Chin Med J (Engl); 2012 Oct; 125(19):3543-7. PubMed ID: 23044321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can levothyroxine treatment reduce urinary albumin excretion rate in patients with early type 2 diabetic nephropathy and subclinical hypothyroidism? A randomized double-blind and placebo-controlled study.
    Liu P; Liu R; Chen X; Chen Y; Wang D; Zhang F; Wang Y
    Curr Med Res Opin; 2015 Dec; 31(12):2233-40. PubMed ID: 26366481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study on treatment of early diabetic nephropathy by tangshenling combined with telmisartan].
    Li JP; He XL; Li Q
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 May; 26(5):415-8. PubMed ID: 16883907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of L-thyroxine substitution on oxidative stress in early-stage diabetic nephropathy patients with subclinical hypothyroidism: a randomized double-blind and placebo-controlled study.
    Chen Y; Wu G; Xu M
    Int Urol Nephrol; 2018 Jan; 50(1):97-103. PubMed ID: 29196928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience of conversion from cyclosporine to tacrolimus prolonged-release in stabilized kidney transplant patients.
    Krejci K; Zadrazil J; Lackova E; Zilinska Z; Roland R; Dedinska I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Sep; 160(3):407-11. PubMed ID: 27174195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
    Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
    Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.